Diuretic Management in Chronic Kidney Disease

Introduction to Diuretic Selection

The American College of Cardiology and other guideline societies recommend loop diuretics as the first-line diuretic choice for patients with CKD, with torsemide being preferred due to its longer duration of action and once-daily dosing, which improves medication adherence in patients with moderate-to-severe CKD (GFR <30 mL/min) 1
Loop diuretics are first-line for managing fluid overload and edema in CKD patients, with twice daily dosing preferred over once daily dosing to maximize effectiveness 2

Torsemide (10-20 mg once daily) is preferred due to its longer duration of action (12-16 hours) compared to furosemide's 6-8 hour duration, in patients with early CKD (Stages 1-3a) 1, 3
Bumetanide can be considered as an alternative with a duration of action of 4-6 hours, in patients with early CKD (Stages 1-3a) 3
Loop diuretics remain effective even with markedly impaired renal function and are preferred over thiazides in patients with GFR <30 mL/min, in advanced CKD (Stages 3b-5) 1

Torsemide is the preferred loop diuretic in CKD due to its longer duration of action (12-16 hours) and once-daily dosing, which improves medication adherence, with a maximum daily dose of 200 mg 1, 3
Furosemide has a shorter duration of action (6-8 hours) requiring more frequent dosing, with a maximum daily dose of 600 mg 3
Bumetanide has a duration of action of 4-6 hours, with a maximum daily dose of 10 mg 3

For resistant edema, consider adding mechanistically different diuretics for synergistic effect, such as adding thiazide-like diuretics to loop diuretics to impair distal sodium reabsorption 2
Options for combination therapy include adding amiloride to counter hypokalemia and improve diuresis, and adding spironolactone to improve edema/hypertension management and counter hypokalemia 2

Monitor for adverse effects of diuretics, including hypokalemia with thiazide and loop diuretics, hyponatremia with thiazide diuretics, impaired GFR, and hyperkalemia with spironolactone and eplerenone, especially if combined with RAS blockade 2
Check serum potassium and renal function within 3 days and again at 1 week after initiation, at least monthly for the first 3 months, and every 3 months thereafter 4

Failing to increase loop diuretic dose in advanced CKD, as higher doses are often needed due to reduced kidney perfusion and fewer nephron sites for drug action 5
Not considering reduced bioavailability of oral diuretics in patients with edema, and neglecting to monitor magnesium levels, as hypomagnesemia can make hypokalemia resistant to correction 4, 5

Dietary sodium restriction (<2.0 g/d or <90 mmol/d) should accompany diuretic therapy, and in patients with both hypertension and proteinuria, ACEi or ARB should be used as first-line therapy, with diuretics added as needed 2

Thiazides lose efficacy below GFR 30 mL/min and should not be used as monotherapy in patients with advanced CKD, according to the American Heart Association 6

In patients with both CKD and cirrhotic ascites, the European Association for the Study of the Liver recommends starting spironolactone 100 mg daily with lower-dose loop diuretics (furosemide 40 mg), as aldosterone antagonists are more effective first-line in this population 7